The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients

Pharmacogenetics and Genomics

Volumn 25, Issue 6, 2015, Pages 313-316

  Batalla, Ana ^a   Coto, Eliecer ^a,b   González Fernández, Daniel ^a   González Lara, Leire ^a   Gómez, Juan ^a   Santos Juanes, Jorge ^a   Queiro, Rubén ^a   Coto Segura, Pablo ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Biological therapy; Gene polymorphism; Late cornified envelope; Pharmacogenetics; Psoriasis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; ETANERCEPT; INFLIXIMAB; CORNIFIED ENVELOPE LIKE PROLINE RICH PROTEIN; HLA C ANTIGEN; HLA-C*06 ANTIGEN; LCE1B PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CW6 GENE; DRUG RESPONSE; FEMALE; GENE; GENE DELETION; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HLA SYSTEM; HUMAN; LATE CORNIFIED ENVELOPE GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENETICS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RISK; STATISTICAL ANALYSIS; ANTAGONISTS AND INHIBITORS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CORNIFIED ENVELOPE PROLINE-RICH PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEQUENCE DELETION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929256174     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000136     Document Type: Article

References (16)

1. Prieto-Perez R, Cabaleiro T, Dauden E, Ochoa D, Roman M, Abad-Santos F. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis 2013;2013:613086.
2. De Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-215.
3. Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012;132:2320-2331.
4. Gonzalez-Lara L, Batalla A, Coto E, Gomez J, Eiris N, Santos-Juanes J, et al. The TNFRSF1B rs1061622 polymorphism (p. M196R) is associated with biological drug outcome in Psoriasis patients. Arch Dermatol Res 2014. [Epub ahead of print].
5. Thomas VD, Yang FC, Kvedar JC. Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 2005;53:346-351.
6. Di Renzo L, Bianchi A, Saraceno R, Calabrese V, Cornelius C, Iacopino L, et al. - 174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-alpha blockers. Pharmacogenet Genomics 2012;22:134-142.
7. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012;22:577-589.
8. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, et al. Genomewide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-581.
9. Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol 2014;171:1181-1188.
10. Gallo E, Cabaleiro T, Roman M, Solano-Lopez G, Abad-Santos F, Garcia-Diez A, et al. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol 2013;169:819-829.
11. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012;132(Pt 1):593-600.
12. Julia M, Guilabert A, Lozano F, Suarez-Casasus B, Moreno N, Carrascosa JM, et al. The role of Fcgamma receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis: a pharmacogenetic study. JAMA dermatology 2013;14:1033-1039.
13. Julia A, Ferrandiz C, Dauden E, Fonseca E, Fernandez-Lopez E, Sanchez-Carazo JL, et al. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J 2014. [Epub ahead of print].
14. Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013;169:458-463.
15. Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW, di Giovine FS. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet 1999;8:1135-1140.
16. Coto E, Santos-Juanes J, Coto-Segura P, Diaz M, Soto J, Queiro R, Alvarez V. Mutation analysis of the LCE3B/LCE3C genes in psoriasis. BMC Med Genet 2010;11:45.